Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Breast Cancer Detection Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Roger Zucchet who wrote (11)	10/13/1998 1:21:00 PM
From: Profiteer	Read Replies (2) \| Respond to of 40

Roger.. You directed your post #7 at me asking a question about BZET! I answered honestly but it was not what you wanted to hear! Sounds like you are the hypester for "bzet" and possibly suffering from schizophrenia! COII is still the Best Early Detection system going..(IMHO)

To: Roger Zucchet who wrote (11)	10/27/1998 10:15:00 AM
From: M&A West, Inc.	Respond to of 40

Lifeline BioTechnologies Added to Group of Biotechnology Leaders On Biospace.com RENO, Nev., Oct. 27 /PRNewswire/ -- Lifeline BioTechnologies Inc. (OTC Bulletin Board: LBTI - news) and Biospace.com announced today the inclusion of Lifeline BioTechnologies to www.biospace.com. A brief company profile and description of Lifeline's leading edge technology are now available on the site. BioSpace(R) is a high-traffic, business-to-business Internet ''hub'' site serving the global biopharmaceutical industry. The overriding goal of BioSpace(R) is to facilitate informed and timely decision-making by providing critical and organized bioscience information in one location on the World Wide Web. BioSpace(R) is an online, on-going industry-specific trade conference which presently attracts over 70,000 visitors monthly looking for the latest news, company information, industry events and career opportunities. These visitors download over 600,000 page views per month from the ''hub'' site -- with a consistent growth rate of 10 percent per month. Lifeline BioTechnologies, Inc.'s (Lifeline) has developed a non-invasive test for early breast cancer detection. The test is incorporated into a proprietary product called First Warning(TM). In preliminary pilot studies, First Warning(TM) demonstrated great promise in detecting formation of extremely early stage breast lesions, particularly in younger women. Management believes the product is an alternative to other breast cancer detection products, including technology from Trex Medical Corporation and Computerized Thermal Imaging, Inc. The second product division under Lifeline BioTechnologies is a line of nutritional food supplements packaged and sold under the tradename NATURE'S CREATIONS. These supplements are marketed and directed towards people afflicted with degenerative diseases that are commonly found in the aging population. These diseases include cancer (breast, colon and prostate) cardiovascular, osteoporosis and mental alertness. For more information on Lifeline BioTechnologies, please visit www.lbti.com. Financial Statements in this press release (if any) other than historical facts are ''forward-looking'' statements with the meaning of section 27A of the Securities Act of 1933, section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements be subject to the safe harbors created thereby. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results. SOURCE: Lifeline BioTechnologies, Inc. --------------------------------------------------------------------------------

To: Roger Zucchet who wrote (11)	11/5/1998 10:12:00 AM
From: M&A West, Inc.	Respond to of 40

Lifeline BioTechnologies Featured in Medical Newsletter, Diagnostic Imaging Scan RENO, Nev.--(BW HealthWire)--Nov. 5, 1998--Lifeline BioTechnologies (OTC BB:LBTI) a leader in early breast cancer detection with its proprietary product, First Warning(tm) was featured in the October 28 issue of Diagnostic Imaging Scan(R). The article highlights First Warning's(tm) groundbreaking technology, a non-invasive breast cancer detection system developed to screen younger women. According to the article, William Reeves, Lifeline's founder, stated, ''There's a big difference between pre- and post-menopausal cancer. Cancer is not an event, it's a process. ''The empirical data would indicate that the milieu for breast cancer is the early childbearing years -- and if you have a technology where you can screen women (at this time), you're way ahead of the game.'' Diagnostic Imaging Scan(R) is a business to business global biweekly newsletter covering the medical imaging market. Lifeline BioTechnologies, Inc.'s (Lifeline) has developed a non-invasive test for early breast cancer detection. The test is incorporated into a proprietary product called First Warning(tm). In preliminary pilot studies, First Warning(tm) demonstrated great promise in detecting formation of extremely early stage breast lesions, particularly in younger women. The second product division under Lifeline BioTechnologies is a line of nutritional food supplements packaged and sold under the tradename NATURE'S CREATIONS. These supplements are marketed and directed towards people afflicted with degenerative diseases that are commonly found in the aging population. These diseases include cancer (breast, colon and prostate) cardiovascular, osteoporosis and mental alertness. For more information on Lifeline BioTechnologies, please visit, lbti.com.

To: Roger Zucchet who wrote (11)	12/20/1998 7:05:00 AM
From: telephonics	Respond to of 40

I recently saw a demonstration of a cancer detection system which startled me. This diagnostic tool,given a small sample of suspect tissue makes a determination on the presence of cancer in only three minutes. Its application is obvious.While a cancer patiuent is still in the operating room the surgeon can obtain a definitive answer to the question (margin) "did I get it all out??" I understand this system has been under evaluation at a major east coast medical institution and they are enthusiastic about its capabilities. This users of the system have also found that this same technology may be useful in determining the onset of a crisis in Sickle Cell Anemia. The device is called DNA ANALYSIS and is the commercialization of technology developed by NASA.